Literature DB >> 2591138

Ethical considerations in the conduct of clinical pharmacokinetic studies.

C K Svensson1.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  1989        PMID: 2591138     DOI: 10.2165/00003088-198917040-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  19 in total

1.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

2.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

3.  Is blood sampling for determination of antipyrine pharmacokinetics in healthy volunteers ethically justified?

Authors:  C K Svensson
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

4.  Vancomycin dosing in preterm infants: prospective verification of new recommendations.

Authors:  G Koren; A James
Journal:  J Pediatr       Date:  1987-05       Impact factor: 4.406

5.  Representation of American blacks in clinical trials of new drugs.

Authors:  C K Svensson
Journal:  JAMA       Date:  1989-01-13       Impact factor: 56.272

6.  Measurement of antipyrine half-life from urinary drug concentrations.

Authors:  G Taylor; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

7.  Single point clearance estimation.

Authors:  J R Koup; J T Slattery; M Gibaldi
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-09

8.  Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?

Authors:  D Long; G Koren; A James
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

9.  Vancomycin pharmacokinetics and dose recommendations for preterm infants.

Authors:  A James; G Koren; J Milliken; S Soldin; C Prober
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

10.  Underrepresentation of women in new drug trials.

Authors:  E L Kinney; J Trautmann; J A Gold; E S Vesell; R Zelis
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

View more
  4 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

3.  Transdermal reverse iontophoresis of valproate: a noninvasive method for therapeutic drug monitoring.

Authors:  M Begoña Delgado-Charro; Richard H Guy
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

4.  Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations.

Authors:  D R Abernethy; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.